haselmeier announces the market launch of juniorstar® by sanofizurich, switzerland, 03 april 2014 &ndash the new and reusable halfunit insulin penjuniorstar® is now available in germany. it is suitable for all insulin types of sanofi. it providesindividual dosage, which can be corrected easily. furthermore, it has a large display to ensurethe correct dosage and is a lightweight companion during the day, especially for young peoplewith diabetes."the launch of juniorstar® marks another milestone of a longterm partnership with sanofi.after the single unit pen tactipen®, the portfolio is now completed by the halfunit penjuniorstar®. the juniorstar® delivers 1 to 30 units in steps of 0.5. thanks to the closecooperation of both teams we were able to develop an excellent pen which meets the currentvery high quality requirements." explains sandra de haan, director project management athaselmeier and responsible project manager for the juniorstar® project."the juniorstar® expands our individual portfolio for people suffering from diabetes. this penoffers, especially young people with type 1 diabetes, a flexible and easy handling to lightentheir lives with diabetes. the excellent and close cooperation with haselmeier was an importantpart for the successful development of the juniorstar® pen." explains hamit oualali, globaldevice manager for reusable pens at sanofi.this pen comes in red, blue and silver for more flexibility and easy differentiation of variousinsulin types.the chicago athenaeum, museum of architecture and design already honoured the juniorstar®pen for its new and fully developed technology with the good design award.about sanofisanofiaventis deutschland gmbh is a company of the sanofi group, a global healthcareleader, which discovers, develops and distributes therapeutic solutions to meet the patients&39needs. sanofi has its core strengths in the field of healthcare with seven growth platformsdiabetes solutions, vaccines, innovative medication, overthecounter health care products,emerging markets, animal health and genzyme.about haselmeierfounded in stuttgart in 1920, haselmeier is now one of the leading designers andmanufacturers of injection systems. the devices feature unique function, design and technologyand are marketed by leading pharmaceutical and biotechnology companies around the world.located in five locations across three continents, we develop and produce innovativetechnologies for administering medication to improve the health and everyday life of patients.please find further information under www.haselmeier.comcontacthaselmeier gmbhdufourstrasse 328008 zurichswitzerlandnadia di secli marketing managertel. 41 44 250 58 50n.secli@haselmeier.com
